Integration of fluxome and transcriptome data in Saccharomyces cerevisiae offers unique features of doxorubicin and imatinib
- 29 June 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Molecular Omics
- Vol. 17 (5) , 783-789
Abstract
Improving the efficacy of drugs and developing new drugs are required to compensate for drug resistance. Therefore, it is critical to unveil the mode of action, which can be studied through the cellular response at genome-scale, of the existing drugs. Here, system-level response of Saccharomyces cerevisiae, a eukaryotic model microorganism, to two chemotherapy drugs doxorubicin and imatinib used against cancer are analysed. While doxorubicin is mainly known to interact with DNA through intercalation and imatinib is known to inhibit the activity of the tyrosine kinase enzyme, the exact mechanisms of action for both drugs have not been determined. The response of S. cerevisiae cells to long-term stress by these drugs under controlled aerobic conditions was investigated and analyzed by the genome-wide transcriptome and genome-wide fluxes. The classification of adverse and similar responses of a certain gene at a transcriptional versus flux level indicated the possible regulatory mechanisms under these different stress conditions. Most of the biochemical reactions were found to be regulated at a post-transcriptional or metabolic level, whereas fewer were regulated at a transcriptional level for both stress cases. Furthermore, disparately induced and repressed pathways in the metabolic network under doxorubicin and imatinib stress were identified. The glycolytic and pentose phosphate pathways responded similarly, whereas the purine–histidine metabolic pathways responded differently. Then, a comparison of differential fluxes and differentially co-expressed genes under doxorubicin and imatinib stress provided the potential common and unique features of these drugs. Analyzing such regulatory differences helps in resolving drug mechanisms and suggesting new drug targets.Keywords
This publication has 44 references indexed in Scilit:
- Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast CancerPLOS ONE, 2013
- Tumor glycolysis as a target for cancer therapy: progress and prospectsMolecular Cancer, 2013
- Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter underlying the action of cysteamine in cystinosis therapyProceedings of the National Academy of Sciences, 2012
- Dissecting DNA damage response pathways by analysing protein localization and abundance changes during DNA replication stressNature Cell Biology, 2012
- Constraining the metabolic genotype–phenotype relationship using a phylogeny of in silico methodsNature Reviews Microbiology, 2012
- Sampling the Solution Space in Genome-Scale Metabolic Networks Reveals Transcriptional Regulation in Key EnzymesPLOS Computational Biology, 2010
- Metabolic systems biologyFEBS Letters, 2009
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols, 2008
- Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene listsNucleic Acids Research, 2008
- Global Gene Expression Analysis of Yeast Cells during Sake BrewingApplied and Environmental Microbiology, 2006